PRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Prenetics Global Ltd (PRE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has shown strong revenue growth driven by its IM8 brand, which has quickly scaled to over $100M in annualized recurring revenue. Despite short-term financial losses, the company's gross margin has improved significantly, and analysts have a positive outlook with a $36 price target, indicating substantial upside potential from the current pre-market price of $17.91. The lack of recent insider or hedge fund activity, along with neutral technical indicators, does not detract from the long-term growth potential of the stock.
The MACD histogram is negative (-0.552) but contracting, indicating a potential reversal. RSI at 46.136 is neutral, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level of 18.648, with key support at 15.764 and resistance at 21.532.
IM8 brand has achieved over $100M in annualized recurring revenue within 11 months.
Recent product launch (Daily Ultimate Essentials PRO) enhances the company's health-focused offerings.
Analyst coverage initiated with a 'Buy' rating and a $36 price target, indicating significant upside potential.
Net income and EPS have declined YoY, reflecting ongoing financial challenges.
No significant insider or hedge fund trading activity, indicating a lack of strong institutional conviction.
In Q3 2025, revenue increased by 567.66% YoY to $23.56M, driven by the success of the IM8 brand. However, net income dropped by -30.58% YoY to -$7.41M, and EPS fell by -36.90% YoY to -0.53. Gross margin improved to 59.54%, up 9.51% YoY, showcasing operational efficiency.
Roth Capital initiated coverage with a 'Buy' rating and a $36 price target, citing the growth potential of the IM8 brand as underappreciated at current share levels.
